host call bladder cancer kol focus bladder cancer treatment
across non-muscl invas muscl invas metastat set
link full note
yesterday fda adcom vote acceler approv ali refractori
ntm also approv front line ntm panelist posit mix
vote vote cultur convers reason conclus indic
clinic efficaci deem risk/reward accept refractori patient
expect approv refractori ntm end
link full note
pleas see addendum report import disclosur
takeaway internet bu tour
conjunct cowen internet bu tour recent host investor meet
jonathan neilson financ director investor relat co
fundament remain strong reiter outperform rate
link full note
said today plan allow use step therapi part drug begin
plan return half save back beneficiari
lower cost share premium begin unlik significantli
reduc drug spend overal depend aggress plan want
could make differ class drug
link full note
year-to-d total semiconductor revenu difficult comp
non-memori revenu data indic non-memori revenu increas
y/i echo industri commentari earn season continu solid
fundament despit us/china polit risk declin
link full note
aircastl benefit invest grade balanc sheet strong liquid
posit concern custom concentr latin america
inabl place aircraft
link full note
pullback share lead buy opportun
believ sell share follow compani earn releas
somewhat unwarr expect stock slight
earn miss declin appear aggress given project
link full note
alder releas financi provid oper updat indic
epti program remain right track recal clinic trial episod chronic
migrain epti continu show impress efficaci achiev quickli
improv continu use consult believ product nice
differenti find nich role add
link full note
galafold launch maintain impress earli momentum expand new
territori like us approv sale continu grow rapidli
investor focu remain pomp program regulatori clariti expect
type meet minut gene therapi deal also expect
remain best idea
link full note
tweak forecast price target continu see highli compel
risk-reward share expect growth profit continu exceed street
expect driven on-going strong growth fb stabil new
custom win major chines data center custom togeth on-going
in-sourc compon product improv
link full note
annual cowen global transport confer around corner
host record public privat compani boston discuss
element global transport marketplac manag team
railroad truck logist rail oem airlin aircraft leas compani join
us present firesid chat panel discuss meet plenti
link full note
bold report today provid encourag efficaci updat pt
posit biopsi data pt xlmtm gene therapi trial
expect next data updat oct second mid-dos cn gene therapi data
remain track ind pomp gt program push
link full note
mark signif progress calx metamorphosi software-centr comm
cloud platform-compani offer larger custom audienc broader solut
set address greater number use case notabl drive margin
improv ahead revenu watch interest remain market perform
given current limit earn power due depress revenue growth
link full note
result cloud continu show momentum
cblk report upsid quarter led healthi growth y/i
cloud revenu growth almost y/i well short-term bill growth
better expect given difficult comp co rais guidanc
reiter outperform rate
link full note
earn glanc
earn glanc
neg total product beat oil miss due higher ngl recoveri
oil guidanc expect signal higher exit believ investor
look complet color becom comfort product
ramp capital-expenditure trend toward low end guidanc capital-expenditure come
lower expect
link full note
neutral result in-lin pre-announce look
hear springboard given import exit start expect
miner right jv topic dividend debt repurchas
better use free cash flow
link full note
 growth concern set persist least possibl earli weigh
overal compani increment margin permian slowdown could depress clb
revenu profit offset growth basin realiz
product enhanc like compani lt outlook return profil
see alreadi healthi valuat hold stock back
link full note
despit challeng multipl reason construct
assum cvr share sell wednesday respons compani
advantag signific pullback posit like sale recoveri
possibl near-term partnership announc neuro increasingli compel
product offer span coronari peripher neuro
link full note
pursu nh jin jiang look radh amadeu may buy travelclick
sold network exit klook asia activ ota rais see
book secret escap uk rais appoint us pe
exec trvg board ac solid
link full note
healthi upsid across board
cybr report good all-around revenu bill ep exceed
expect well guidanc rais encourag improv
execut cybr last quarter said perpetu licens model
trade cybr appear somewhat fairli valu current level
link full note
updat pro-forma estim reflect earn report
asid cost synergi continu sold strateg rational
deal compani face tough domest affili comp slow intern
growth reiter market perform rate share
link full note
result ahead consensu revenu y/i vs
adj ebitda vs management reiter guid note adj
ebitda like mid- low-end guid due start delay fl health
system end see time issu affect reiter
outperform would buyer weak
link full note
expeditor intern washington
benefit favor tax rate beat consensu ep
estim without benefit would slightli beaten estim
miss consensu leav ep estim virtual unchang
modestli rais number maintain market perform rate
link full note
revenu light vs street due longer convers complex ts deal
off-set notabl bullish bpm pipeline/bookings/larg deal commentari
demonstr margin improv bp q/q ge stabil bp increas
revenue guid a/organ affirm om/ep guid posit outweigh
neg view attract rel valuat
link full note
gw pharma report financi includ net loss cash
balanc epidiolex on-track reschedul end
septemb launch shortli thereaft tonight gw announc price
per year think enabl broad access think gw
under-valued epidiolex maintain price target
link full note
expect flagship smartphon launch season strength drive
growth display benefit outperform rate lg display
in-display fingerprint sensor appear like becom prefer biometr
authent android model limit n-t upsid himx market perform
scan could play futur role main camera side
link full note
solid qtr/guid surfac mix signal number maintain pt
hdp post solid upsid rev/op profit rais guidanc howev bill miss
our/street est guidanc upsid seem less account
drag origin anticip share may seem relief ralli estim move
higher see result bit mix remain sidelin due end-market
link full note
ichor immun near term soft across semicap landscap
resili oper model full display septq remain inexpens
way play myriad posit driver spe cross sell opportun across
broaden custom base support above-wf growth
discount
link full note
strong broad-bas upsid result guidanc reinforc invest thesi
drive signific increas estim price target see upsid
driven iivi leadership posit divers number long-tail high-growth larg
opportun togeth opportun signific margin upsid reiter
link full note
beat revenu volum expect even adjust compani
success effort captur revenu associ volum
compani increas fy revenu guidanc third time year expect revenu
grow year compound-annual-growth-rate yet share trade sale materi
discount peer would buyer current level
link full note
although manag alter vyxeo launch trajectori believ out-
year target still track consult continu indic perform
clinic exactli hope given kol feedback unconcern short-
term focu long remaind portfolio cash gener solid
overal thesi much intact add weak
link full note
takeaway flash memori summit firesid chat
manag reinforc recent view quarter correct memori wfe
spend demand improv nand scale beyond layer
die stack beyond chip appear technic feasibl expect
key beneficiari
link full note
myovant report net loss end
cash relugolix pivot phase program endometriosi uterin fibroid
prostat cancer progress result anticip expect
myovant outperform relugolix advanc develop onto
link full note
bill growth beat consensu strong qtr smb
enterpris enterpris number new account
trend higher infrastructur monitor highest attach product
impli broader platform strategi gain steam continu see strong
durabl growth aid digit secular tailwind pt
link full note
ocular provid oper updat recal dextenza dec pdufa date
manag indic fda perform manufactur inspect
shortli given possibl approv year-end previous survey cataract
surgeon potenti use dextenza result favor
republish note remain cautious optimist
link full note
earn glanc
slightli posit believ expect low come result
account adjust creat appear higher permian ga cut
strong ip prime strong growth especi
elimin midland oil price exposur
link full note
earn glanc
posit ebitda beat high end con fleet deliv
fleet deliv expect commentari solid outlook
well notabl given permian exposur see potenti upsid
ebitda vs current con assum fleet work flat
link full note
solid tymlo watch sustain share gain momentum
solid led continu stronger project tymlo sale share
progress firm anabol market grew alreadi
lower end appar flatten nrx share growth coupl
unchang full year guidanc suggest pace share gain could temper vs
hing impact return strateg market effort
link full note
report morn announc zulresso brexanolon adcomm
increment color upcom commerci launch strategi new clinic program
oral bipolar depress well mdd sleep studi data
track start pivot mdd lt safeti studi
link full note
salesforc promot keith block co-ceo
think keith block promot co-ceo posit develop sharehold
near-term given time think impli strong medium-term think
block could usher budget-consci strategi around growth resourc
alloc could lift margin expans long-term block success make
strateg enterpris vendor persist
link full note
result mix better ad revenu off-set user declin
snap post mix result come revenue expect light user
growth deceler y/i dau declin q/q disrupt
redesign revenu guid lower midpoint reflect redesign price
declin shift auction ebitda guid better tweak estimate pt
unchang maintain under-perform share flat ah
link full note
sunesi report financi includ net loss pro-forma cash
manag report suffici fund oper
vecabrutinib phase trial cell malign continu enrol expand
cohort efficaci expect manag remain hope
select rpiid fall remain market perform
link full note
continu encourag oper result outperform
expect reflect continu trokendi inflect
migrain manag team continu execut trokendi oxtellar
continu gain traction provid nice cash flow invest
proprietari portfolio also allow even flexibl bd
link full note
sndx updat includ guidanc tighter opex manag balanc
encor data decis push
third pre-specifi os check novemb provid potl nt catalyst given street
temper expect step melanoma nsclc share ye trial
explor chronic gvhd new start ye
link full note
report net loss end june cash
suffici fund oper data on-going dose escal cohort
phase trial anticip expans cohort begin
enrol fall data combo therapi arm on-going phase ii studi
also report remain outperform
link full note
thought elon tweet go privat offer
chairman ceo elon musk announc via consid
take compani privat highlight mani unansw question around
transact well compani need addit fund regardless
structur mr musk claim fund place detail spars
link full note
textain continu grow earn driven strong
fundament wit across industri demand new use
contain remain robust valu appear cap near-term
link full note
startup/transit cost set ep growth
report result broadli line estim ep impact
one-tim item custom pursuit lower lcoe lead transit
line startup impact profit short term improv
profit beyond new contract extens improv visibl
contract revenu
link full note
vlrx post solid result reiter guidanc busi outlook
near term cash runway improv strong recent us execut intern
contribut ramp next year howev despit reason valuat
ev/ continu believ cash burn capit
structur render risk/reward balanc
link full note
cash balanc suffici fund oper earli
vy-aadc pivot program parkinson diseas progress one site
activ select expect share outperform gene therapi
link full note
disney report revenu ep estim consensu
see degrad consum product also show sustain soft maintain
market perform rate price target caution around acquisit
link full note
xoma report net loss end june cash
suffici fund oper multipl year xoma continu focu becom
royalti aggreg licens compani continu rate xoma share market
perform await better visibl abil royalti portfolio drive
link full note
zafgen report net loss recent equiti offer
resourc suffici fund oper track enter
phase studi higher dose data track earli
continu view share fairli valu await suffici clinic data defin
safeti efficaci profil
link full note
war gop under-perform double-digit
wave fizzl hous senat remain gop
last midterm wave perfect three-of-last-
three wave
day midterm
link full note
import disclosur inform relat cowen washington research group
